Catheter infection lawsuits are mass tort cases alleging that implantable medical devices—particularly central venous access ports—have caused serious infections, blood clots, and other life-threatening complications. These legal actions target manufacturers like C.R. Bard and AngioDynamics over devices designed to deliver medications and nutrients directly into the bloodstream. The most prominent example is Robert Cook, a cancer patient who received a Bard PowerPort implantable catheter, only to develop a severe infection that required emergency removal of the device, a PICC line insertion for antibiotics, and additional surgery.
The scope of catheter infection litigation has expanded dramatically. The Bard PowerPort multidistrict litigation (MDL 3081) saw cases surge from 1,410 filed lawsuits in May 2025 to 3,187 by May 2026—a 126% increase in a single year. Current consolidated claims total approximately 3,384 lawsuits as of May 2026. Meanwhile, AngioDynamics faces 269 centralized cases in its own MDL 3125 involving identical allegations: that defective catheter designs increase the risk of infections and other serious injuries.
Table of Contents
- What Are the Major Catheter Infection Lawsuits?
- How Do Catheter Infections Develop and What Makes These Devices Defective?
- What Are Bellwether Trials and How Do They Advance Catheter Infection Cases?
- How Much Can You Recover in a Catheter Infection Lawsuit?
- What Specific Device Defects Are Alleged in Catheter Infection Cases?
- AngioDynamics and Other Implantable Port Manufacturers
- The Future of Catheter Infection Litigation
- Conclusion
- Frequently Asked Questions
What Are the Major Catheter Infection Lawsuits?
The Bard PowerPort litigation represents the largest active catheter infection litigation in the United States. These lawsuits allege that the device’s polyurethane catheter components, blended with barium sulfate, are prone to fracturing, migrating, eroding through surrounding tissue, and causing infections. Plaintiffs contend that C.R. Bard failed to adequately warn physicians and patients about these risks, allowing patients to receive implants without full knowledge of potential complications.
AngioDynamics faces similar allegations across 269 consolidated lawsuits in MDL 3125, filed in the U.S. District Court for the Southern District of California under Judge Jinsook Ohta. The cases also center on defective design and inadequate warnings, with injuries ranging from blood clots to life-threatening infections. Unlike some mass torts that resolve quickly, catheter infection cases are advancing slowly through the litigation system—a reminder that federal judges managing these cases are taking time to establish which claims have merit before allowing settlements.
How Do Catheter Infections Develop and What Makes These Devices Defective?
Catheter infections, medically referred to as central line-associated bloodstream infections (CLABSI), occur when bacteria or fungi colonize the catheter and enter the bloodstream. These infections can lead to sepsis, organ failure, and death. The lawsuits allege that certain implantable ports are more susceptible to these infections because their design allows bacteria to accumulate along fractures or rough surfaces created by material degradation. When a polyurethane catheter weakens and cracks, it creates an ideal environment for microbial growth and biofilm formation—a protective layer that antibiotics cannot penetrate.
The core defect alleged in the Bard PowerPort cases is that the polyurethane-barium sulfate blend weakens over time, particularly when exposed to body chemistry and normal movement. This degradation increases the risk of fracture, erosion, and migration—all conditions that can lead to infection. Manufacturers allegedly knew or should have known about these risks based on clinical data and previous complaints but failed to issue adequate warnings. A critical limitation of these cases is that proving a specific catheter caused a specific infection can be challenging; hospital records must establish that the infection originated from the device rather than from contamination during insertion or from other sources.
What Are Bellwether Trials and How Do They Advance Catheter Infection Cases?
Bellwether trials are test cases selected to go to trial first in a mass tort litigation. They serve as indicators of how juries and judges view similar claims, and their outcomes often influence settlement negotiations for thousands of remaining cases. The first Bard PowerPort bellwether trial was scheduled for April 21, 2026, featuring Robert Cook’s case—the cancer patient whose PowerPort implant became infected, requiring emergency surgical removal and aggressive antibiotic treatment through a PICC line.
Five additional bellwether trials are scheduled through February 2027, each addressing specific types of device failures: catheter fracture, infection, and thrombosis (blood clots). These staggered trials will provide crucial data about how juries respond to different injury scenarios. However, bellwether trials also carry risk for plaintiffs; if the first case results in a defense verdict or minimal award, it can dampen enthusiasm among remaining claimants and weaken negotiating positions in settlement discussions.
How Much Can You Recover in a Catheter Infection Lawsuit?
Settlement amounts in hospital-acquired infection cases typically average around $250,000, according to malpractice claims data. However, cases involving wrongful death or permanent disability regularly result in seven-figure settlements—often exceeding $1 million. The variation in settlement values depends on several factors: the severity of the infection, whether the plaintiff developed permanent complications, the impact on life expectancy and quality of life, the cost of ongoing medical care, and lost wages.
To illustrate the financial impact, consider that a single central line-associated bloodstream infection costs approximately $46,000 in direct medical expenses, according to CDC data. A patient who developed a severe infection and required months of hospitalization, multiple surgeries, and lifelong antibiotic management would likely have a much larger claim than someone whose infection was caught early and treated with IV antibiotics alone. Additionally, the economic analysis in these cases often includes expert testimony on future medical costs, loss of earning capacity, and pain and suffering—elements that significantly increase settlement values in cases involving permanent injury.
What Specific Device Defects Are Alleged in Catheter Infection Cases?
The lawsuits specifically allege that C.R. Bard’s choice to use polyurethane blended with barium sulfate created a catheter material prone to degradation. Barium sulfate is a radiopaque agent added to make catheters visible on X-rays, but critics argue that this additive compromises the structural integrity of the polyurethane, making it weaker and more susceptible to fracturing under normal physiological conditions. When these fractures occur, they create rough edges and crevices where bacteria can anchor and form biofilms.
One significant limitation of these defect theories is that not every patient with a fractured catheter develops an infection. Some patients’ immune systems or clinical management prevent infection from taking hold. This means that proving causation—that the specific device caused the specific infection—requires detailed medical records and expert testimony establishing a direct connection between the device failure and the patient’s infection. The defendants argue that many catheter infections result from insertion technique, inadequate site care, or contamination, not device design. These competing theories about causation will be central to the bellwether trials and any eventual settlement negotiations.
AngioDynamics and Other Implantable Port Manufacturers
AngioDynamics faces 269 consolidated lawsuits (MDL 3125) with similar allegations to those against Bard. The claims focus on defective design and insufficient warnings regarding infection and thrombosis risks. While AngioDynamics litigation is smaller than the Bard cases, it represents a second major front in implantable catheter litigation, suggesting that the problem may extend across the industry rather than being limited to a single manufacturer.
The centralization of AngioDynamics cases in California under Judge Jinsook Ohta means that discovery and trial scheduling will proceed on a separate timeline from the Bard MDL. This geographic separation can create advantages and disadvantages for plaintiffs; different federal courts have different procedural approaches and jury pools may view medical device cases differently. As of December 2025, no bellwether trials had been scheduled in the AngioDynamics litigation, meaning these cases may take longer to reach resolution than the Bard cases moving toward trial in 2026.
The Future of Catheter Infection Litigation
With six bellwether trials scheduled through February 2027, the catheter infection mass tort is entering a critical phase. The outcomes of these early trials will likely determine whether Bard settles its remaining 3,300+ claims en masse or continues litigating individual cases. Settlements in comparable device litigation have ranged from modest amounts for less severe cases to multimillion-dollar payouts for wrongful death or permanent injury.
Plaintiffs’ lawyers are monitoring the FDA’s regulatory response to these devices as well. Adverse event reports, warning letters, and any regulatory actions could strengthen the allegation that manufacturers knew about risks but failed to warn. Meanwhile, technological improvements in catheter design and insertion protocols continue to evolve, raising the question of whether future devices will avoid these pitfalls. For patients currently considering implantable ports, discussing these risks with physicians remains important—informed consent conversations should specifically address infection risk and what to watch for if a port is implanted.
Conclusion
Catheter infection lawsuits represent a significant mass tort affecting thousands of patients who received implantable ports for cancer treatment, dialysis, or other serious conditions. The Bard PowerPort litigation alone involves over 3,300 consolidated cases, with a 126% increase in claims over just one year, while the AngioDynamics litigation adds another 269 cases alleging identical defects. Settlement values in these cases typically range from $250,000 to over $1 million, depending on infection severity and long-term medical consequences.
If you received a Bard PowerPort or similar implantable catheter and developed a serious infection requiring hospitalization or surgical removal, you may be eligible to pursue a claim. Contact a law firm experienced in medical device litigation to review your medical records and determine whether your case qualifies for the existing MDLs. The bellwether trials scheduled through February 2027 will provide important guidance on how courts and juries view these claims, making this an active and evolving area of mass tort law.
Frequently Asked Questions
What is the difference between a bellwether trial and a settlement?
A bellwether trial is a test case that goes to trial and produces a jury verdict, which then informs settlement negotiations for similar cases. Settlements are negotiated agreements where both sides agree to a payment without going to trial. Bellwether trials help establish baseline damages that influence settlement offers for remaining claims.
How much does a central line infection cost to treat?
A single central line-associated bloodstream infection (CLABSI) costs approximately $46,000 in direct medical expenses. However, costs can exceed $100,000 when accounting for extended hospitalization, multiple surgeries, long-term antibiotic therapy, and complications like sepsis.
Are all implantable catheter infections the result of device defects?
No. Some infections result from insertion technique, inadequate site care, contamination, or patient factors. The lawsuits allege that certain devices increase infection risk through defective design, but proving causation requires medical evidence that the device failure directly caused the infection.
How long do catheter infection cases typically take to resolve?
Bellwether trials in the Bard PowerPort litigation began in April 2026, with additional trials scheduled through February 2027. Mass settlement agreements typically follow 12-18 months after bellwether results are available. Individual cases not included in settlement negotiations may take 3-5 years or longer to resolve.
Can I join a catheter infection lawsuit if my device hasn’t failed yet?
Generally, no. Most lawsuits require proof of actual injury—an infection that occurred, treatment required, or other documented medical harm. If you have an implanted device and have not experienced complications, you likely do not have a viable claim at this time.
How do I know if I’m eligible to join the Bard PowerPort MDL?
You must have received a Bard PowerPort implant and developed a documented infection or other serious complication (fracture, migration, blood clot) that required medical treatment. Contact a medical device litigation attorney to review your medical records and determine eligibility for MDL 3081 or other related claims.